{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:20:17Z","timestamp":1783059617969,"version":"3.54.6"},"reference-count":21,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T00:00:00Z","timestamp":1396569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>T\u2010cell lymphomas (TCLs) are uncommon in the United States. The accurate diagnosis of TCL is challenging and requires morphologic interpretation, immunophenotyping, and molecular techniques. The authors compared pathologic diagnoses at referring centers with diagnoses from expert hematopathology review to determine concordance rates and to characterize the usefulness of second\u2010opinion pathology review for TCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients in the National Comprehensive Cancer Network non\u2010Hodgkin lymphoma database with peripheral TCL, not otherwise specified (PTCL\u2010NOS), angioimmunoblastic TCL (AITL), and anaplastic lymphoma kinase (ALK)\u2010positive and ALK\u2010negative anaplastic large cell lymphoma (ALCL) were eligible if they had prior tissue specimens examined at a referring institution. Pathologic concordance was evaluated using available pathology and diagnostic testing reports and provider progress notes. The etiology of discordance and the potential impact on treatment were examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Among 131 eligible patients, 57 (44%) had concordant results, totaling 64% of the 89 patients who were referred with a final diagnosis. Thirty\u2010two patients (24%) had discordant results, representing 36% of those who were referred with a final diagnosis. The rates of discordance among patients with of PTCL\u2010NOS, AITL, ALK\u2010negative ALCL, and ALK\u2010positive ALCL were 19%, 33%, 34%, and 6%, respectively. In 14 patients (44% of discordant results), pathologic reclassification could have resulted in a different therapeutic strategy. Forty\u2010two patients (32%) were referred for classification with a provisional diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>In a large cohort of patients with TCL who were referred to National Comprehensive Cancer Network centers, the likelihood of a concordant final diagnosis at a referring institution was low. As current and future therapies target TCL subsets, these data suggest that patients with suspected TCLs would benefit from evaluation by an expert hematopathologist. <jats:bold><jats:italic>Cancer<\/jats:italic> 2014;120:1993\u20131999<\/jats:bold>. \u00a9 <jats:italic>2014 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.28676","type":"journal-article","created":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T11:08:46Z","timestamp":1396609726000},"page":"1993-1999","source":"Crossref","is-referenced-by-count":38,"title":["Comparison of referring and final pathology for patients with T\u2010cell lymphoma in the National Comprehensive Cancer Network"],"prefix":"10.1002","volume":"120","author":[{"given":"Alex F.","family":"Herrera","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Crosby\u2010Thompson","sequence":"additional","affiliation":[{"name":"Division of Population Sciences Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, James P. Wilmot Cancer Center University of Rochester Rochester New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Abel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Roswell Park Cancer Institute Buffalo New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Deparment of Hematology\u2010Oncology Northwestern University Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology University of Michigan Comprehensive Cancer Center Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Millenson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fox Chase Cancer Center Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auayporn P.","family":"Nademanee","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation City of Hope Cancer Center Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce C.","family":"Niland","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation City of Hope Cancer Center Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Rodig","sequence":"additional","affiliation":[{"name":"Department of Pathology Brigham and Women's Hospital Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, Division of Cancer Medicine The University of Texas M. D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Department of Medicine Memorial Sloan\u2010Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2345"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00815.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00856.x"},{"key":"e_1_2_7_6_1","first-page":"1272","article-title":"Long\u2010term disease\u2010free survival in patients with angioimmunoblastic T\u2010cell lymphoma after high\u2010dose chemotherapy and autologous stem cell transplantation","volume":"88","author":"Schetelig J","year":"2003","journal-title":"Haematologica."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.0188"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf033"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.1102"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-310342"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3647"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.2223"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4061"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.5611"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28676","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:35:32Z","timestamp":1760297732000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,4]]},"references-count":21,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1002\/cncr.28676"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28676","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,4]]}}}